Impact of the early reduction of cyclosporine on renal function in heart transplant patients: A French randomised controlled trial

9Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Using reduced doses of Cyclosporine A immediately after heart transplantation in clinical trials may suggest benefits for renal function by reducing serum creatinine levels without a significant change in clinical endpoints. However, these trials were not sufficiently powered to prove clinical outcomes.Methods: In a prospective, multicentre, open-label, parallel-group controlled trial, 95 patients aged 18 to 65 years old, undergoing de novo heart transplantation were centrally randomised to receive either a low (130 < trough CsA concentrations <200 μg/L, n = 47) or a standard dose of Cyclosporine A (200 < trough CsA concentrations <300 μg/L, n = 48) for the three first post-transplant months along with mycophenolate mofetil and corticosteroids. Participants had a stable haemodynamic status, a serum creatinine level <250 μmol/L and the donors' cold ischemia time was under six hours; multiorgan transplants were excluded. The change in serum creatinine level over 12 months was used as the main criterion for renal function. Intention-to-treat analysis was performed on the 95 randomised patients and a mixed generalised linear model of covariance was applied.Results: At 12 months, the mean (± SD) creatinine value was 120.7 μmol/L (± 35.8) in the low-dose group and 132.3 μmol/L (± 49.1) in the standard-dose group (P = 0.162). Post hoc analyses suggested that patients with higher creatinine levels at baseline benefited significantly from the lower Cyclosporine A target. The number of patients with at least one rejection episode was not significantly different but one patient in the low-dose group and six in the standard-dose group required dialysis.Conclusions: In patients with de novo cardiac transplantation, early Cyclosporine A dose reduction was not associated with renal benefit at 12 months. However, the strategy may benefit patients with high creatinine levels before transplantation.Trial registration: ClinicalTrials.gov NCT00159159. © 2012 Boissonnat et al.; licensee BioMed Central Ltd.

References Powered by Scopus

Chronic renal failure after transplantation of a nonrenal organ

1943Citations
N/AReaders
Get full text

Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection

1565Citations
N/AReaders
Get full text

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients

545Citations
N/AReaders
Get full text

Cited by Powered by Scopus

A contemporary review of adult heart transplantation: 2012 to 2013

23Citations
N/AReaders
Get full text

Risk factors for chronic renal insufficiency following cardiac transplantation

20Citations
N/AReaders
Get full text

Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: A systematic review and meta-analysis

15Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Boissonnat, P., Gaillard, S., Mercier, C., Redonnet, M., Lelong, B., Mattei, M. F., … Gueyffier, F. (2012). Impact of the early reduction of cyclosporine on renal function in heart transplant patients: A French randomised controlled trial. Trials, 13. https://doi.org/10.1186/1745-6215-13-231

Readers over time

‘13‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘25036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

67%

Researcher 4

27%

Professor / Associate Prof. 1

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 12

71%

Agricultural and Biological Sciences 2

12%

Biochemistry, Genetics and Molecular Bi... 2

12%

Nursing and Health Professions 1

6%

Save time finding and organizing research with Mendeley

Sign up for free
0